Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review

Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment option in the fight against advanced non-small-cell lung cancer (NSCLC). KRAS is the most frequently mutated oncogene in NSCLC. We performed this meta-analysis to investigate if KRAS mutation status affects survival benefits o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jung Han, Kim, Hyeong Su, Kim, Bum Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564642/
https://www.ncbi.nlm.nih.gov/pubmed/28525386
http://dx.doi.org/10.18632/oncotarget.17594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564642/
https://www.ncbi.nlm.nih.gov/pubmed/28525386
http://dx.doi.org/10.18632/oncotarget.17594

Ejemplares similares